Apollomics (NASDAQ:APLM) Trading Down 1.3% – Time to Sell?

Shares of Apollomics Inc. (NASDAQ:APLM) fell 1.3% on Monday . The company traded as low as $18.43 and last traded at $19.00. 2,894 shares traded hands during trading, a decline of 79% from the average session volume of 13,538 shares. The stock had previously closed at $19.25.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Apollomics in a research note on Monday, December 29th. Wall Street Zen upgraded Apollomics from a “sell” rating to a “hold” rating in a report on Saturday, January 17th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Apollomics Stock Performance

The business has a fifty day simple moving average of $18.66 and a 200 day simple moving average of $15.32.

About Apollomics

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.